Deciphering EIF3D's Role in Immune Regulation and Malignant Progression: A Pan-Cancer Analysis with a Focus on Colon Adenocarcinoma

Overview

Journal J Inflamm Res

Publisher Dove Medical Press

Date 2024 Oct 7

PMID 39372593

Authors

Yiming Zhou

Rui Chai

Yongxiang Wang

Xiaojun Yu

Affiliations

Soon will be listed here.

Abstract

Background: EIF3D, a key component of the eukaryotic translation initiation factor 3 (EIF3) complex, is critical in selectively translating mRNAs with atypical cap structures. Its relationship with colon adenocarcinoma (COAD) development and immune infiltration, however, remains under-explored. This study delves into EIF3D's role in COAD using bioinformatics and in vitro experimentation.

Materials And Methods: We analyzed EIF3D expression levels utilizing TCGA, GTEx, CPTAC, and TISIDB databases. The TISCH database and ssGSEA method helped in assessing EIF3D's link with the tumor immune microenvironment. EIF3D expression in CRC cells was gauged via real-time PCR. Cell proliferation was assessed using CCK8 and colony formation assays, while migration capabilities were tested through Transwell assays. Flow cytometry facilitated cell cycle distribution and apoptosis analysis. ChIP-qPCR identified transcription factors regulating EIF3D, and bulk sequencing explored EIF3D's pathways in promoting COAD.

Results: EIF3D upregulation is a common feature in various tumors, especially in COAD, correlating with poor prognosis in many cancer types. It showed significant associations with immune cell and cancer-associated fibroblast (CAF) infiltration across multiple tumors. Additionally, it is closely associated with molecular and immune subtypes of multiple tumors, including COAD. Single-cell analyses depicted EIF3D's distribution and proportion in CRC immune cells. In vitro findings indicated EIF3D knockdown curtailed proliferation and migration, inducing G0/G1 arrest in COAD cells. Moreover, bulk sequencing revealed EIF3D knockdown interferes with multiple cancer-related pathways, likely by curtailing cell cycle and DNA replication activities to regulate cell proliferation.

Conclusion: EIF3D emerges as a potential prognostic biomarker for tumor progression and immune infiltration, particularly in COAD, potentially predicting immunotherapy efficacy. Additionally, EIF3D represents a multifaceted target implicated in COAD's malignant progression.

References

Zhang W, Sun Y, Bai L, Zhi L, Yang Y, Zhao Q . RBMS1 regulates lung cancer ferroptosis through translational control of SLC7A11. J Clin Invest. 2021; 131(22). PMC: 8592553. DOI: 10.1172/JCI152067. View

Yasunaga M . Antibody therapeutics and immunoregulation in cancer and autoimmune disease. Semin Cancer Biol. 2019; 64:1-12. DOI: 10.1016/j.semcancer.2019.06.001. View

Latosinska A, Mokou M, Makridakis M, Mullen W, Zoidakis J, Lygirou V . Proteomics analysis of bladder cancer invasion: Targeting EIF3D for therapeutic intervention. Oncotarget. 2017; 8(41):69435-69455. PMC: 5642490. DOI: 10.18632/oncotarget.17279. View

Pitt J, Marabelle A, Eggermont A, Soria J, Kroemer G, Zitvogel L . Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy. Ann Oncol. 2016; 27(8):1482-92. DOI: 10.1093/annonc/mdw168. View

Fridman W, Zitvogel L, Sautes-Fridman C, Kroemer G . The immune contexture in cancer prognosis and treatment. Nat Rev Clin Oncol. 2017; 14(12):717-734. DOI: 10.1038/nrclinonc.2017.101. View

Fridman W, Pages F, Sautes-Fridman C, Galon J . The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012; 12(4):298-306. DOI: 10.1038/nrc3245. View

He J, Wang X, Cai J, Wang W, Qin X . High expression of eIF3d is associated with poor prognosis in patients with gastric cancer. Cancer Manag Res. 2017; 9:539-544. PMC: 5661832. DOI: 10.2147/CMAR.S142324. View

Siegel R, Miller K, Wagle N, Jemal A . Cancer statistics, 2023. CA Cancer J Clin. 2023; 73(1):17-48. DOI: 10.3322/caac.21763. View

Noy R, Pollard J . Tumor-associated macrophages: from mechanisms to therapy. Immunity. 2014; 41(1):49-61. PMC: 4137410. DOI: 10.1016/j.immuni.2014.06.010. View

10.

Luen S, Salgado R, Dieci M, Vingiani A, Curigliano G, Gould R . Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy. Ann Oncol. 2018; 30(2):236-242. DOI: 10.1093/annonc/mdy547. View

11.

Ciesla M, Ngoc P, Cordero E, Martinez A, Morsing M, Muthukumar S . Oncogenic translation directs spliceosome dynamics revealing an integral role for SF3A3 in breast cancer. Mol Cell. 2021; 81(7):1453-1468.e12. DOI: 10.1016/j.molcel.2021.01.034. View

12.

Riley R, June C, Langer R, Mitchell M . Delivery technologies for cancer immunotherapy. Nat Rev Drug Discov. 2019; 18(3):175-196. PMC: 6410566. DOI: 10.1038/s41573-018-0006-z. View

13.

Shen W, Song Z, Zhong X, Huang M, Shen D, Gao P . Sangerbox: A comprehensive, interaction-friendly clinical bioinformatics analysis platform. Imeta. 2024; 1(3):e36. PMC: 10989974. DOI: 10.1002/imt2.36. View

14.

Du W, Cheng H, Peng L, Yang D, Yang C . hmiR-34c-3p upregulation inhibits the proliferation of colon cancer cells by targeting EIF3D. Anticancer Drugs. 2018; 29(10):975-982. DOI: 10.1097/CAD.0000000000000674. View

15.

Shen S, Chen L, Liu J, Yang L, Zhang M, Wang L . Current state and future of co-inhibitory immune checkpoints for the treatment of glioblastoma. Cancer Biol Med. 2020; 17(3):555-568. PMC: 7476097. DOI: 10.20892/j.issn.2095-3941.2020.0027. View

16.

Ma S, Dong Z, Huang Y, Liu J, Zhang J . eIF3a regulation of mTOR signaling and translational control via HuR in cellular response to DNA damage. Oncogene. 2022; 41(17):2431-2443. PMC: 9035104. DOI: 10.1038/s41388-022-02262-5. View

17.

Wang D, Jia Y, Zheng W, Li C, Cui W . Overexpression of in Lung Adenocarcinoma Is a New Independent Prognostic Marker of Poor Survival. Dis Markers. 2019; 2019:6019637. PMC: 6925810. DOI: 10.1155/2019/6019637. View

18.

Lin Y, Zhang R, Zhang P . Eukaryotic translation initiation factor 3 subunit D overexpression is associated with the occurrence and development of ovarian cancer. FEBS Open Bio. 2017; 6(12):1201-1210. PMC: 5302064. DOI: 10.1002/2211-5463.12137. View

19.

Pan X, Chen L, Hong Y, Xu D, Liu X, Li L . EIF3D silencing suppresses renal cell carcinoma tumorigenesis via inducing G2/M arrest through downregulation of Cyclin B1/CDK1 signaling. Int J Oncol. 2016; 48(6):2580-90. DOI: 10.3892/ijo.2016.3459. View

20.

Mendoza-Reinoso V, Baek D, Kurutz A, Rubin J, Koh A, McCauley L . Unique Pro-Inflammatory Response of Macrophages during Apoptotic Cancer Cell Clearance. Cells. 2020; 9(2). PMC: 7072562. DOI: 10.3390/cells9020429. View